Advertisement

Journal of Endocrinological Investigation

, Volume 37, Issue 8, pp 769–773 | Cite as

Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods

  • Andrea MessoriEmail author
  • Valeria Fadda
  • Dario Maratea
  • Sabrina Trippoli
  • Claudio Marinai
Rapid Communication

Abstract

Background

In the present study, we undertook an equivalence analysis on the effectiveness of the main anti-reabsorptive agents indicated for women with osteoporosis.

Methods

Our methodology was a combination of meta-analysis (both pair-wise meta-analysis and network meta-analysis) and equivalence testing. The end-point was the incidence on new vertebral fractures. The anti-reabsorptive agents examined included alendronate, zoledronate, ibandronate, risedronate, and denosumab.

Results

Our analysis involved nine randomized trials. Ten head-to-head indirect comparisons were examined through network meta-analysis and the respective values of RR were estimated. The 95 % confidence intervals for RR remained within the interval of a relative ±40 % variation for all comparisons that involved alendronate, risedronate, ibandronate, and denosumab. In contrast, the comparisons involving zoledronate satisfied a post hoc margin up to ±67 %.

Conclusion

Our results confirm that most of these anti-reabsorptive drugs (namely, alendronate, risedronate, ibandronate, and denosumab) are equivalent according to reasonable equivalence margins.

Keywords

Meta-analysis Equivalence Osteoporosis Ibandronate Alendronate Risedronate Denosumab 

Notes

Conflict of interest

None.

References

  1. 1.
    Ahn S, Park SH, Lee KH (2013) How to demonstrate similarity by using noninferiority and equivalence statistical testing in radiology research. Radiology 267(2):328–338PubMedCrossRefGoogle Scholar
  2. 2.
    Messori A, Fadda V, Maratea D, Trippoli S (2014) The Italian way to evidence-based demonstration of equivalence as a prerequisite for conducting procurement tendering within the NHS (Rapid Response), thebmj. http://www.bmj.com/content/347/bmj.f4951/rr/759376. Accessed 1 July 2014
  3. 3.
    Migliore A, Broccoli S, Massafra U, Cassol M, Frediani B (2013) Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. Eur Rev Med Pharmacol Sci 17(5):658–667PubMedGoogle Scholar
  4. 4.
    Norman G, Monteiro S, Salama S (2012) Sample size calculations: should the emperor’s clothes be off the peg or made to measure? BMJ 23(345):e5278. doi: 10.1136/bmj.e5278 CrossRefGoogle Scholar
  5. 5.
    Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA (2014) Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 189(3):250–255PubMedCrossRefGoogle Scholar
  6. 6.
    Fadda V, Maratea D, Trippoli S, Messori A (2011) Network meta-analysis. Results can be summarised in a simple figure. BMJ 23(342):d1555CrossRefGoogle Scholar
  7. 7.
    Messori A (2014) Comment, PubMed Commons. Available at http://www.ncbi.nlm.nih.gov/pubmed/23543450/#comments. Accessed 5 Apr 2014
  8. 8.
    Arruda MA (2013) No evidence of efficacy or evidence of no efficacy. JAMA Pediatr 167(3):300–302PubMedCrossRefGoogle Scholar
  9. 9.
    Messori A, Fadda V, Maratea D, Trippoli S (2013) Erythropoiesis-stimulating agents in heart failure: no proof of effectiveness or proof of no effectiveness? Eur J Heart Fail 15(8):944–945PubMedCrossRefGoogle Scholar
  10. 10.
    Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24(1):209–217PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2014

Authors and Affiliations

  • Andrea Messori
    • 1
    Email author
  • Valeria Fadda
    • 1
  • Dario Maratea
    • 1
  • Sabrina Trippoli
    • 1
  • Claudio Marinai
    • 2
  1. 1.HTA UnitArea Vasta Centro Toscana Regional Health SystemFlorenceItaly
  2. 2.Department of Pharmaceutical LogisticsESTAV Toscana Centro, Regional Health ServiceFlorenceItaly

Personalised recommendations